Breaking News Instant updates and real-time market news.

RTRX

Retrophin

$20.08

-1.31 (-6.12%)

, CARA

Cara Therapeutics

$11.97

0.27 (2.31%)

04:55
11/20/16
11/20
04:55
11/20/16
04:55

American Society of Nephrology to hold a conference

ASN Kidney Week 2016 is being held in Chicago on November 15-20.

RTRX

Retrophin

$20.08

-1.31 (-6.12%)

CARA

Cara Therapeutics

$11.97

0.27 (2.31%)

CCXI

ChemoCentryx

$7.98

0.04 (0.50%)

ANTH

Anthera

$1.83

-0.06 (-3.17%)

  • 29

    Nov

RTRX Retrophin
$20.08

-1.31 (-6.12%)

11/11/16
LEER
11/11/16
NO CHANGE
LEER
Outperform
Retrophin agreement for RE-024 bodes well for approval in 2019, says Leerink
Leerink analyst Joseph Schwartz says that the trial design for Retrophin's pending Phase 3 trial of RE-024 and the announced agreement with the FDA under the Special Protocol Assessment process for this trial bode well for potential approval in 2019. The analyst believes the company plans to initiate this trial by the end of 2016, with a drug that has shown "great promise" for the treatment of pantothenate kinase-associated neurodegeneration. He reiterates an Outperform rating on the shares.
09/08/16
BMOC
09/08/16
NO CHANGE
BMOC
Retrophin price target raised to $40 from $28 at BMO Capital
BMO Capital analyst Do Kim raised the price target on Retrophin after the company reported Phase II data for its Sparsentan drug that the analyst views positively. Kim now sees a 45% chance of success for the drug, up from 25% previously. The analyst keeps an Outperform rating on the shares.
09/07/16
LEER
09/07/16
NO CHANGE
LEER
Outperform
Retrophin price target raised to $32 from $27 at Leerink
Leerink analyst Joseph Schwartz said he is "very optimistic" that sparsentan will be approved after Retrophin announced top-line results for its Phase 2b DUET study. However, he thinks it is still unclear if the results reported today will be enough to support accelerated approval or if another clinical trial will be required. Schwartz raised his price target on Retrophin to $32 from $27 following the data release and keeps an Outperform rating on the shares.
09/07/16
ROTH
09/07/16
NO CHANGE
Target $151
ROTH
Buy
Ligand target raised to $151 after sparsentan data at Roth Capital
Roth Capital analyst Joseph Pantginis raised his price target for Ligand Pharmaceuticals (LGND) to $151 from $149 after the company's partner Retrophin (RTRX) announced positive data from the sparsentan Phase II study in focal segmental glomerulosclerosis patients. The analyst believes the data support a potential accelerated path forward and he reminds investors that FSGS has no approved therapies. Pantginis calls the data an important win for Ligand and Retrophin. He keeps a Buy rating on Ligand. The stock is up 7% to $115.21 in early trading.
CARA Cara Therapeutics
$11.97

0.27 (2.31%)

12/31/15
PIPR
12/31/15
NO CHANGE
Target $34
PIPR
Overweight
Cara Therapeutics called a top 2016 pick at Piper Jaffray
Piper Jaffray analyst Charles Duncan highlights Cara Therapeutics (CARA) as his top pick going into 2016. The analyst likens the company's position to Neurocrine's (NBIX) last year, which he points out gained 150% at the end of 2014 to present. Cara has "notable value creation" potential from two Phase III read-outs of candidates with a "well-vetted mechanism of action in large-market indications," Duncan tells investors in a New Year's Eve research note. The analyst expects Cara's peak sales to reach four times its current market capitalization. He recommends buying the stock ahead of the Phase III readouts and keeps an Overweight rating on the stock with a $34 price target. Duncan expects the company to begin a pivotal trial of IV'845 in uremic pruritus in early 2016, with data being announced likely in Q4. Cara closed yesterday down 33c to $15.79 with a market cap of just below $440M.
02/26/16
CANT
02/26/16
NO CHANGE
CANT
Delay caused by Cara Therapeutics hold will be short, says Cantor
After Cara announced a clinical hold on the Phase III trial of its IV CR845 drug for post-surgical pain, the firm thinks the hold was unnecessary and does not expect it to delay the drug's advancement for more than three months. Cantor keeps a $28 price target and Buy rating on the shares.
10/13/16
HCWC
10/13/16
INITIATION
Target $20
HCWC
Buy
Cara Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Corey Davis started Cara Therapeutics with a Buy rating and $20 price target. The company's CR845 presents an opportunity treat peripheral pain without addiction potential, the analyst contends.
CCXI ChemoCentryx
$7.98

0.04 (0.50%)

ANTH Anthera
$1.83

-0.06 (-3.17%)

11/11/16
SBSH
11/11/16
NO CHANGE
Target $6
SBSH
Buy
Anthera price target lowered to $6 from $10 at Citi
Citi analyst Yigal Nochomovitz lowered his price target for Anthera Pharmaceuticals to $6 after the company announced that its Phase III trial failed to meet the primary endpoint in systemic lupus erythematosus. The result is not a "huge surprise" as the program always carried high risk, Nochomovitz tells investors in a research note. The analyst keeps a Buy rating on the shares, citing significantly higher conviction for Sollpura. He recommends buying on yesterday's weakness.
07/08/16
07/08/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Yelp (YELP) initiated with a Neutral at Wedbush. 2. PayPal (PYPL) initiated with an Overweight at Stephens. 3. GrubHub (GRUB) initiated with an Outperform at Wedbush. 4. Anthera (ANTH) initiated with a Buy at H.C. Wainwright. 5. 58.com (WUBA) initiated with an Outperform at Macquarie. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/08/16
HCWC
07/08/16
INITIATION
Target $10
HCWC
Buy
Anthera initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein initiated Anthera with a Buy and $10 price target saying shares are attractive ahead of the Sollpura topline data expected by year-end.
03/29/16
SBSH
03/29/16
NO CHANGE
SBSH
Citi lays out potential targets for next biotech M&A wave
Citi analyst Yigal Nochomovitz believes the setup for the next acquisition cycle in the biotech space is here, but that biotech management's desire to do deals is the missing catalyst. He thinks another one-to-three quarters is needed before "reset valuations are better absorbed as the new reality." Large cap pharma and biotech companies are cash rich and have signaled repeatedly over last year that they are looking for new assets, Nochomovitz tells investors in a research note. He sees a "greater probability" of a takeover over the next 12-18 months for Ardelyx (ARDX), Medivation (MDVN), Ophthotech (OPHT), Puma Biotechnology (PBYI), Portola Pharmaceuticals (PTLA), Ultragenyx (RARE), Relypsa (RLYP) and Versartis (VSAR). He sees a "moderate probability" of a takeover for Anthera (ANTH), Loxo Oncology (LOXO), MacroGenics (MGNX) and Mirati Therapeutics (MRTX). Nochomovitz also sees a "lower probability" of a buyout for Atara Biotherapeutics (ATRA), Chimerix (CMRX), Keryx (KERX) and Mirna Therapeutics (MIRN).

TODAY'S FREE FLY STORIES

AETI

American Electric Tech.

$1.75

-0.05 (-2.78%)

09:32
12/05/16
12/05
09:32
12/05/16
09:32
Hot Stocks
American Electric Tech. unit awarded contract in Trinidad »

American Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GWB

Great Western

09:31
12/05/16
12/05
09:31
12/05/16
09:31
Conference/Events
Great Western management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

HIL

Hill International

09:31
12/05/16
12/05
09:31
12/05/16
09:31
Hot Stocks
Hill International receives $15.5M facilities management contract from ADNOC »

Hill International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$59.25

0.05 (0.08%)

, GOOG

Alphabet

$750.50

2.58 (0.34%)

09:30
12/05/16
12/05
09:30
12/05/16
09:30
Periodicals
Microsoft's Home Hub to go beyond Google Home, Amazon Echo, Windows Central says »

Microsoft's rumored…

MSFT

Microsoft

$59.25

0.05 (0.08%)

GOOG

Alphabet

$750.50

2.58 (0.34%)

GOOGL

Alphabet Class A

$764.46

0.13 (0.02%)

AMZN

Amazon.com

$740.34

-3.31 (-0.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jan

CLC

Clarcor

, PH

Parker-Hannifin

09:30
12/05/16
12/05
09:30
12/05/16
09:30
Recommendations
Clarcor, Parker-Hannifin analyst commentary  »

Clarcor price target…

CLC

Clarcor

PH

Parker-Hannifin

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 19

    Dec

  • 20

    Dec

ASUR

Asure Software

$8.48

0.21 (2.54%)

09:30
12/05/16
12/05
09:30
12/05/16
09:30
Hot Stocks
Asure Software appoints Eyal Goldstein as Chief Revenue Officer »

Asure Software announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

BDC

Belden

09:30
12/05/16
12/05
09:30
12/05/16
09:30
Earnings
Belden sees FY16 adjusted EPS $5.20-$5.30, consensus $5.24 »

Sees FY16 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

09:30
12/05/16
12/05
09:30
12/05/16
09:30
General news
Chicago Fed dove Evans sees growth picking up »

Chicago Fed dove Evans…

BDC

Belden

09:29
12/05/16
12/05
09:29
12/05/16
09:29
Earnings
Belden sees Q4 adjusted EPS $1.36-$1.46, consensus $1.40 »

Sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

BDC

Belden

09:28
12/05/16
12/05
09:28
12/05/16
09:28
Hot Stocks
Breaking Hot Stocks news story on Belden »

Belden to confirm Q4,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

INWK

InnerWorkings

$9.20

0.25 (2.79%)

09:28
12/05/16
12/05
09:28
12/05/16
09:28
Hot Stocks
InnerWorkings, GateHouse Media announce multi-year affiliation »

InnerWorkings and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

STC

Stewart

09:28
12/05/16
12/05
09:28
12/05/16
09:28
Downgrade
Stewart rating change  »

Stewart downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MEET

MeetMe

09:27
12/05/16
12/05
09:27
12/05/16
09:27
Earnings
MeetMe sees FY revenue $74.5M-$76M, consensus $75.11M »

Adjusted EBITDA for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

OPTT

Ocean Power

$3.23

0.04 (1.25%)

09:27
12/05/16
12/05
09:27
12/05/16
09:27
Hot Stocks
Ocean Power, Sonalysts announce joint marketing agreement »

Ocean Power Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIMO

Gigamon

, VZ

Verizon

09:27
12/05/16
12/05
09:27
12/05/16
09:27
Recommendations
Gigamon, Verizon, AT&T, T-Mobile, Amazon.com analyst commentary  »

Gigamon setting up well…

GIMO

Gigamon

VZ

Verizon

T

AT&T

TMUS

T-Mobile

$54.44

0.18 (0.33%)

AMZN

Amazon.com

$740.34

-3.31 (-0.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 07

    Dec

  • 07

    Dec

  • 13

    Dec

  • 24

    Jan

MEET

MeetMe

09:27
12/05/16
12/05
09:27
12/05/16
09:27
Earnings
MeetMe sees Q4 revenue $27.5M-$29M, consensus $28.2M »

Adjusted EBITDA for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

MOS

Mosaic

09:26
12/05/16
12/05
09:26
12/05/16
09:26
Recommendations
Mosaic analyst commentary  »

Mosaic estimates lowered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MEET

MeetMe

09:26
12/05/16
12/05
09:26
12/05/16
09:26
Hot Stocks
MeetMe reports U.S. mobile CPMs up 14% y/y in November »

MeetMe said that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

MEET

MeetMe

09:26
12/05/16
12/05
09:26
12/05/16
09:26
Hot Stocks
Breaking Hot Stocks news story on MeetMe »

MeetMe reiterates Q4, FY…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

MCD

McDonald's

09:26
12/05/16
12/05
09:26
12/05/16
09:26
Technical Analysis
McDonald's extends its recent recovery »

The stock was last at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FRP

FairPoint

$17.00

0.25 (1.49%)

, CNSL

Consolidated Communications

$28.38

0.11 (0.39%)

09:25
12/05/16
12/05
09:25
12/05/16
09:25
Hot Stocks
On The Fly: Pre-market Movers »

FairPoint Communications…

FRP

FairPoint

$17.00

0.25 (1.49%)

CNSL

Consolidated Communications

$28.38

0.11 (0.39%)

CHK

Chesapeake

BLCM

Bellicum Pharmaceuticals

$18.72

1.74 (10.25%)

MRVL

Marvell

$14.02

0.04 (0.29%)

KITE

Kite Pharma

$50.76

0.04 (0.08%)

CERC

Cerecor

$1.75

-0.24 (-12.06%)

ETP

Energy Transfer Partners

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 14

    Dec

ICE

IntercontinentalExchange

09:25
12/05/16
12/05
09:25
12/05/16
09:25
Hot Stocks
IntercontinentalExchange reports November futures ADV up 12% »

Intercontinental Exchange…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

QURE

uniQure

$5.68

-0.31 (-5.18%)

09:25
12/05/16
12/05
09:25
12/05/16
09:25
Conference/Events
uniQure to host investor breakfast meeting »

Investor breakfast…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 08

    Dec

BSFT

BroadSoft

$40.30

-0.35 (-0.86%)

09:25
12/05/16
12/05
09:25
12/05/16
09:25
Conference/Events
BroadSoft to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

SSNLF

Samsung

09:23
12/05/16
12/05
09:23
12/05/16
09:23
Conference/Events
Samsung management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

  • 07

    Dec

  • 08

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.